NAQ
NAQ is a potent and selective μ opioid receptor partial agonist, with a Ki of 0.55 nM. NAQ shows selectivity for Mu opioid receptor over the δ receptor (Ki=132.50 nM) and the κ receptor (Ki=26.45 nM). NAQ can be used for the research of opioid withdrawal or dependence.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 分子式: C30H31N3O4
- 分子量:497.58
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
Opioid Receptor アイソフォーム固有の製品をすべて表示
More
生物活性
製品説明
IC50 & Target
[1]|
μ Opioid Receptor/MOR 0.55 nM (Ki) |
κ Opioid Receptor/KOR 26.45 nM (Ki) |
δ Opioid Receptor/DOR 132.50 nM (Ki) |
体外実験
NAQ is a μ opioid receptor (MOR) partial agonist, with an EC50 of 4.36 nM in MOR-expressing CHO cell line[1].
NAQ (45 min) inhibits hERG with an IC50 of 220 nM in CHO-K1 cells stably transfected with human hERG cDNA[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
体内実験
NAQ (0.32-10 mg/kg; s.c.) produces weak intracranial self-stimulation (ICSS) facilitation in rats but more robust ICSS facilitation during and after Morphine treatment and also reverses Morphine withdrawal-associated depression of ICSS[2].
Pharmacokinetics of NAQ in rats[3]
| t1/2 (min) |
Vss (L/kg) |
CL(mL/min/kg) | AUCInf (h⋅ng/mL) |
Tmax (min) |
Cmax (ng/mL) |
F (%) |
|
| 1 mg/kg IV | 32.4 | 3.0 | 86 | 202 | / | / | / |
| 10 mg/kg PO | / | / | / | 114 | 36 | 20 | 3 |
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
化学情報
-
分子量 497.58
-
分子式 C30H31N3O4
-
SMILES
O=C(C1=CC2=C(C=N1)C=CC=C2)N[C@H]3[C@@H]4[C@]56C7=C(O4)C(O)=CC=C7C[C@@H](N(CC8CC8)CC6)[C@@]5(O)CC3
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
純度とドキュメンテーション
参考文献
[1]. Li G, et, al. Design, synthesis, and biological evaluation of 6alpha- and 6beta-N-heterocyclic substituted naltrexamine derivatives as mu opioid receptor selective antagonists. J Med Chem. 2009 Mar 12;52(5):1416-27. [Content Brief]
[2]. Altarifi AA, et, al. Effects of the novel, selective and low-efficacy mu opioid receptor ligand NAQ on intracranial self-stimulation in rats. Psychopharmacology (Berl). 2015 Feb;232(4):815-24. [Content Brief]
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
NAQ 関連分類
HY-151811 関連分類
Powered by Bioz